CA-ADSWIZZ
17.2.2021 12:02:05 CET | Business Wire | Press release
AdsWizz, the leading global technology provider for digital audio advertising solutions, has been certified by the IAB Tech Lab as Open Measurement Software Development Kit (OM SDK) compliant. This is the first time an audio ad-tech provider has had their SDK certified for OM SDK compliance, enabling “audibility” verification of audio ads. With this in place, publishers and advertisers can now know for certain whether an ad was heard or not.
“Advertisers coming from video and display, where standards like this are in place, need validation that their investment in audio is safe,” said Erik Barraud, SVP of Product Management at AdsWizz. “That is why we continue to lead the industry and embrace standards that help us – and all of our partners – give advertisers assurance and peace of mind when it comes to audio advertising.”
AdsWizz’s SDK reaches over 500 million unique devices globally and is used by some of the world’s largest audio publishers, such as TuneIn in the U.S.; Bauer Media and Wireless in the U.K.; M6 and NRJ in France; Crossplan Deutschland Publishers in Germany; ARN, SCA and NZME in Australia and New Zealand. Pandora and SoundCloud adoption are planned for later this year. By enabling audibility verification, not only do advertisers receive certainty that their ad was heard, but they are also able to verify this against the largest footprint of audiences listening to premium audio content.
AdsWizz’s SDK is a versatile piece of technology that powers unique advertising capabilities, such as interactive ad formats. AdsWizz ShakeMe and AdsWizz Voice Ads allow the listener to interact with the ad by shaking their phone or giving a voice response, respectively. The interactive responses can download an app or coupon, take the listener to a website to learn more, deliver directions to a store location, and more.
“The Open Measurement SDK was created to bring transparency and consistency to in-app advertising,” said Shailley Singh, Vice President, Product Management and Global Programs, IAB Tech Lab. “The adoption of the OM SDK by AdsWizz brings the lessons learned in web and display to lay the foundation for open and transparent audio advertising.”
The OM SDK, released by IAB Tech Lab in April 2018, was originally designed to facilitate third-party viewability and verification measurement for ads served to web video and mobile app environments. The recent certification of the AdsWizz SDK uses the recent version 1.3 of the OM SDK that supports audio measurement for the first time, taking the same third-party verification measurement standards and applying them to audio ads for audibility. To classify as an “audible” ad, the audio ad must play for 2 seconds with the player unmuted.
The AdsWizz OM SDK certification by IAB Tech Lab applies globally. AdsWizz SDK 7.2 was released in October 2020 and is available to publishers using the AdsWizz Campaign Manager (AudioServe) in all global markets.
About AdsWizz
AdsWizz has created the end-to-end technology platform that is powering the digital audio advertising ecosystem. AdsWizz is the underlying monetization solution for well-known music platforms, podcasts and broadcasting groups worldwide. Through dynamic ad insertion, advanced programmatic platforms, and innovative audio formats, AdsWizz efficiently connects buyers and sellers for digital audio and podcast advertising. AdsWizz is owned by SiriusXM, and is headquartered in San Mateo, California, with a Technology Development Hub in Bucharest, Romania.
About IAB Tech Lab
Established in 2014, the IAB Technology Laboratory (Tech Lab) is a non-profit consortium that engages a member community globally to develop foundational technology and standards that enable growth and trust in the digital media ecosystem. Comprised of digital publishers, ad technology firms, agencies, marketers, and other member companies, IAB Tech Lab focuses on solutions for brand safety and ad fraud; identity, data, and consumer privacy; ad experiences and measurement; and programmatic effectiveness. Its work includes the OpenRTB real-time bidding protocol, ads.txt anti-fraud specification, Open Measurement SDK for viewability and verification, VAST video specification, and the Project Rearc initiative for privacy-centric addressability. Board members/companies are listed at: https://iabtechlab.com/about-the-iab-tech-lab/tech-lab-leadership/
. For more information, please visit: https://iabtechlab.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005266/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom